-
Century Therapeutics (IPSC) files for 176.09M share offering by selling stockholders
-
Century Therapeutics (IPSC) PT Raised to $4 at Piper Sandler
-
Century Therapeutics (IPSC) PT Lowered to $6.60 at Clear Street
-
Century Therapeutics board member resigns effective December 18
-
Leerink Partners Downgrades Century Therapeutics (IPSC) to Market Perform
-
Century Therapeutics, Inc. (IPSC) Misses Q3 EPS by 1c
-
Century Therapeutics launches diabetes program targeting immune rejection
-
Century Therapeutics, Inc. (IPSC) Reports In-Line Q2 EPS
-
Century Therapeutics (IPSC) Files $200M Mixed Shelf
-
Century Therapeutics (IPSC) to Cut 51% Staff, Announces CFO Departure
-
Century Therapeutics, Inc. (IPSC) Tops Q1 EPS by 96c
-
H.C. Wainwright Reiterates Buy Rating on Century Therapeutics (IPSC)
-
Century Therapeutics (IPSC) PT Lowered to $2 at H.C. Wainwright
-
Century Therapeutics (IPSC) PT Lowered to $5 at Guggenheim
-
Century Therapeutics (IPSC) Reports Full Year 2024 Financial Results and Provides Business Update
-
Century Therapeutics (IPSC) Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned
-
Century Therapeutics (IPSC) PT Slashed to $4 at Piper Sandler Following Termination of the Bristol-Myers Alliance
-
Clear Street Starts Century Therapeutics (IPSC) at Buy
-
Century Therapeutics (IPSC) PT Lowered to $5 at H.C. Wainwright
-
Century Therapeutics (IPSC) Announces Appointments of Chief Financial Officer and Chief Scientific Officer
-
Century Therapeutics (IPSC) PT Lowered to $9 at H.C. Wainwright
-
Century Therapeutics, Inc. (IPSC) Tops Q2 EPS by 7c
-
Century Therapeutics (IPSC) PT Raised to $12 at Piper Sandler

